See every side of every news story
Published loading...Updated

Xeltis Reports Preliminary Data For Coronary Artery Bypass Conduit - Data Intelligence

The EU study aims to assess the Xabg technology in patients with multi-vessel atherosclerotic coronary artery disease who are scheduled for elective CABG surgery. Credit: Photoroyalty / Shutterstock.com. Xeltis has reported positive preliminary data for its Xabg coronary artery bypass conduit (CABG) in a clinical trial that is underway at various European Union (EU) sites. The data from the trial indicated positive safety and patency for individ…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

4 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Cardiovascular News broke the news in on Thursday, July 17, 2025.
Sources are mostly out of (0)

Similar News Topics